Eupraxia Pharmaceuticals (EPRX) News Today $5.15 -0.12 (-2.26%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Buy" by AnalystsAugust 23, 2025 | americanbankingnews.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Earns "Buy" Rating from HC WainwrightAugust 22, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Eupraxia Pharmaceuticals (NASDAQ:EPRX)August 22, 2025 | americanbankingnews.comEupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 20, 2025 | marketbeat.comEPRX FY2025 EPS Forecast Lowered by Cantor FitzgeraldAugust 19, 2025 | marketbeat.comFY2025 EPS Estimates for EPRX Cut by Cantor FitzgeraldAugust 19, 2025 | americanbankingnews.comQ3 EPS Estimate for Eupraxia Pharmaceuticals Cut by AnalystAugust 17, 2025 | marketbeat.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Quarterly Earnings Results, Misses Expectations By $0.05 EPSAugust 14, 2025 | marketbeat.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 13, 2025 | finanznachrichten.deEupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | globenewswire.comScotia Capital Inc. Boosts Stock Holdings in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX)August 5, 2025 | marketbeat.comEupraxia Pharmaceuticals (EPRX) Expected to Announce Quarterly Earnings on WednesdayJuly 31, 2025 | marketbeat.comCantor Fitzgerald Forecasts EPRX FY2025 EarningsJuly 28, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX)July 25, 2025 | marketbeat.comEupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Rating of "Buy" from AnalystsJuly 24, 2025 | marketbeat.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 2.3% - Time to Sell?July 23, 2025 | marketbeat.comEupraxia Pharmaceuticals Invited to Present at Upcoming Investor ConferencesJuly 22, 2025 | financialpost.comFEupraxia Pharmaceuticals Invited to Present at Upcoming Investor ConferencesJuly 22, 2025 | financialpost.comFEupraxia Pharmaceuticals Invited to Present at Upcoming Investor ConferencesJuly 22, 2025 | globenewswire.comEupraxia Pharmaceuticals (EPRX) Receives a Buy from Raymond JamesJuly 11, 2025 | theglobeandmail.comEupraxia Pharma Shares Climb on Dosing of First EP-104GI Study PatientJuly 8, 2025 | marketwatch.comEupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic EsophagitisJuly 8, 2025 | globenewswire.comQ2 Earnings Estimate for EPRX Issued By HC WainwrightJune 30, 2025 | marketbeat.comEupraxia Pharmaceuticals Stock Short Interest Report | NASDAQ:EPRX - BenzingaJune 27, 2025 | benzinga.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded by HC Wainwright to "Strong-Buy" RatingJune 27, 2025 | marketbeat.comEupraxia Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:EPRX - BenzingaJune 26, 2025 | benzinga.comEupraxia Pharma director buys as stock tests top of rangeJune 26, 2025 | theglobeandmail.comHC Wainwright & Co. Initiates Coverage of Eupraxia Pharmaceuticals (EPRX) with Buy RecommendationJune 26, 2025 | msn.comThis NRG Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayJune 26, 2025 | benzinga.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Analysts at Canaccord Genuity GroupJune 16, 2025 | marketbeat.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 0.8% - Should You Sell?June 6, 2025 | marketbeat.comEupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest UpdateJune 5, 2025 | marketbeat.comEupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersJune 2, 2025 | globenewswire.comEupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025May 7, 2025 | financialpost.comFEupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025May 7, 2025 | globenewswire.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 7, 2025 | finanznachrichten.deEupraxia Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 6, 2025 | globenewswire.comEupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and MayApril 24, 2025 | financialpost.comFEupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and MayApril 24, 2025 | financialpost.comFEupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and MayApril 24, 2025 | globenewswire.comEupraxia Pharmaceuticals IncApril 8, 2025 | uk.investing.comEupraxia Pharmaceuticals (EPRX) Projected to Post Earnings on MondayMarch 31, 2025 | marketbeat.comRaymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)March 25, 2025 | markets.businessinsider.comHere's Why We're Watching Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn SituationMarch 22, 2025 | finance.yahoo.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Earnings ResultsMarch 21, 2025 | marketbeat.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial ResultsMarch 21, 2025 | finanznachrichten.deEupraxia Pharmaceuticals reports FY24 EPS (76c), consensus (63c)March 21, 2025 | markets.businessinsider.comEupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial ResultsMarch 20, 2025 | prnewswire.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 1.7% - What's Next?March 18, 2025 | marketbeat.comEupraxia Pharmaceuticals management to meet virtually with Craig-HallumMarch 4, 2025 | markets.businessinsider.com Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EPRX Media Mentions By Week EPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPRX News Sentiment▼0.611.03▲Average Medical News Sentiment EPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPRX Articles This Week▼31▲EPRX Articles Average Week Get the Latest News and Ratings for EPRX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Eupraxia Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Tango Therapeutics News Today ArriVent BioPharma News Today Oculis News Today Niagen Bioscience News Today Dianthus Therapeutics News Today Phathom Pharmaceuticals News Today Gyre Therapeutics News Today Nurix Therapeutics News Today Amylyx Pharmaceuticals News Today Mind Medicine (MindMed) News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EPRX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access